pirenzepine has been researched along with Acute Confusional Senile Dementia in 38 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and tolerability of olanzapine in the treatment of significant anxiety symptoms in patients with AD." | 9.09 | Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. ( Breier, A; Faison, W; Mintzer, J; Street, JS; Sutton, VK, 2001) |
| "To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease." | 8.82 | Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. ( Schatz, RA, 2003) |
| " This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline." | 5.09 | The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. ( Breier, A; Clark, WS; Feldman, PD; Street, JS, 2001) |
| "To assess the efficacy and tolerability of olanzapine in the treatment of significant anxiety symptoms in patients with AD." | 5.09 | Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. ( Breier, A; Faison, W; Mintzer, J; Street, JS; Sutton, VK, 2001) |
| "To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease." | 4.82 | Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. ( Schatz, RA, 2003) |
| "In vitro receptor characterization methods, when done using physiologically relevant conditions allow accurate prediction of the relatively low rate of anticholinergic-like adverse events, extrapyramidal symptoms, and cardiovascular adverse events during treatment with OLZ." | 2.41 | A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. ( Baker, RW; Beasley, CM; Bernauer, M; Breier, A; Bymaster, FP; Calligaro, DO; Dossenbach, M; Effron, MB; Felder, CC; Hay, D; Holcombe, JH; Kaiser, C; Kennedy, JS; Kinon, BJ; Nomikos, G; Roth, HJ; Schuh, L, 2001) |
| "Tacrine was found to biphasically both increase (10(-6) and 5 x 10(-6) M) and decrease (10(-5)-10(-4) M) the release of ACh in a concentration-dependent manner." | 1.29 | Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. ( Nordberg, A; Svensson, AL; Zhang, X, 1996) |
| "These results suggest that cases of Alzheimer's disease express heterogeneities in neocortical pathology which are reflected in the laminar patterns of binding to postsynaptic receptors." | 1.28 | Laminar alterations in gamma-aminobutyric acidA, muscarinic, and beta adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer's disease. ( Crino, PB; Vogt, BA; Volicer, L, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.53) | 18.7374 |
| 1990's | 13 (34.21) | 18.2507 |
| 2000's | 21 (55.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jenkins, SM | 1 |
| Wadsworth, HJ | 1 |
| Bromidge, S | 1 |
| Orlek, BS | 1 |
| Wyman, PA | 1 |
| Riley, GJ | 1 |
| Hawkins, J | 1 |
| Friedman, JH | 1 |
| Fernandez, HH | 1 |
| Mulugeta, E | 1 |
| Karlsson, E | 1 |
| Islam, A | 1 |
| Kalaria, R | 1 |
| Mangat, H | 1 |
| Winblad, B | 2 |
| Adem, A | 2 |
| Piggott, MA | 1 |
| Owens, J | 1 |
| O'Brien, J | 1 |
| Colloby, S | 1 |
| Fenwick, J | 1 |
| Wyper, D | 1 |
| Jaros, E | 1 |
| Johnson, M | 1 |
| Perry, RH | 1 |
| Perry, EK | 1 |
| Edell, WS | 2 |
| Rupnow, MF | 1 |
| Schatz, RA | 1 |
| Reeves, RR | 1 |
| Torres, RA | 1 |
| Hoeh, N | 1 |
| Gyulai, L | 1 |
| Weintraub, D | 1 |
| Streim, J | 1 |
| Tsang, SW | 2 |
| Lai, MK | 2 |
| Kirvell, S | 1 |
| Francis, PT | 1 |
| Esiri, MM | 1 |
| Hope, T | 1 |
| Chen, CP | 2 |
| Wong, PT | 2 |
| Pomakian, J | 1 |
| Marshall, GA | 1 |
| Vinters, HV | 1 |
| Cummings, JL | 2 |
| Caulfield, MP | 1 |
| Straughan, DW | 1 |
| Cross, AJ | 1 |
| Crow, T | 1 |
| Birdsall, NJ | 1 |
| Ladner, CJ | 2 |
| Celesia, GG | 1 |
| Magnuson, DJ | 1 |
| Lee, JM | 2 |
| Ferrari-DiLeo, G | 2 |
| Mash, DC | 2 |
| Flynn, DD | 3 |
| Vestling, M | 1 |
| Cowburn, RF | 1 |
| Venizelos, N | 1 |
| Lannfelt, L | 1 |
| Plate, R | 1 |
| Plaum, MJ | 1 |
| de Boer, T | 1 |
| Andrews, JS | 1 |
| Rae, DR | 1 |
| Gibson, S | 1 |
| Svensson, AL | 1 |
| Zhang, X | 1 |
| Nordberg, A | 1 |
| Wolfgang, SA | 1 |
| Jeste, DV | 2 |
| Street, JS | 4 |
| Clark, WS | 3 |
| Gannon, KS | 1 |
| Bymaster, FP | 3 |
| Tamura, RN | 1 |
| Mitan, SJ | 2 |
| Kadam, DL | 2 |
| Sanger, TM | 1 |
| Feldman, PD | 3 |
| Tollefson, GD | 1 |
| Breier, A | 6 |
| Simard, M | 1 |
| van Reekum, R | 1 |
| Leslie, DL | 1 |
| Rosenheck, R | 1 |
| Tunis, SL | 1 |
| Carter, PA | 1 |
| DeLapp, NW | 1 |
| Calligaro, DO | 2 |
| Felder, CC | 2 |
| Schneider, LS | 1 |
| Tariot, PN | 1 |
| Lyketsos, CG | 1 |
| Dagerman, KS | 1 |
| Davis, KL | 1 |
| Davis, S | 1 |
| Hsiao, JK | 1 |
| Katz, IR | 1 |
| Olin, JT | 1 |
| Pollock, BG | 1 |
| Rabins, PV | 1 |
| Rosenheck, RA | 1 |
| Small, GW | 1 |
| Lebowitz, B | 1 |
| Lieberman, JA | 1 |
| Kennedy, JS | 2 |
| Zagar, A | 1 |
| Bymaster, F | 1 |
| Nomikos, G | 2 |
| Trzepacz, PT | 1 |
| Gilmore, JA | 1 |
| Rotelli, MD | 1 |
| Tollefson, G | 1 |
| Schuh, L | 1 |
| Bernauer, M | 1 |
| Kinon, BJ | 1 |
| Baker, RW | 1 |
| Hay, D | 1 |
| Roth, HJ | 1 |
| Dossenbach, M | 1 |
| Kaiser, C | 1 |
| Beasley, CM | 1 |
| Holcombe, JH | 1 |
| Effron, MB | 1 |
| Juliar, BE | 1 |
| Mintzer, J | 1 |
| Faison, W | 1 |
| Sutton, VK | 1 |
| Vogt, BA | 1 |
| Crino, PB | 1 |
| Volicer, L | 1 |
| Pearce, BD | 1 |
| Potter, LT | 1 |
| Weinstein, DA | 1 |
| Araujo, DM | 1 |
| Lapchak, PA | 1 |
| Robitaille, Y | 1 |
| Gauthier, S | 1 |
| Quirion, R | 1 |
| Vanderheyden, P | 1 |
| Ebinger, G | 1 |
| Dierckx, R | 1 |
| Vauquelin, G | 1 |
| Watson, M | 1 |
| Vickroy, TW | 1 |
| Roeske, WR | 1 |
| Yamamura, HI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for pirenzepine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Humans; Mental Disorders; Olanzapine; Pire | 2003 |
Pharmacologic management of psychosis in the elderly: a critical review.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm | 2003 |
Dementia with Lewy bodies in Down's syndrome.
Topics: Adolescent; Adult; Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depr | 2001 |
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alzheimer Disease; Animals; Benzodiazepines; Brain; D | 2001 |
7 trials available for pirenzepine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; P | 1999 |
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepin | 2000 |
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Delus | 2001 |
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit | 2001 |
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzodiazepines; Brain; Cholinergic Fibers; Dose-Respons | 2001 |
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Benzodiazepines; Dose-Response Rela | 2001 |
Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anxiety; Benzodiazepines; Dose-Response Relationship, Dr | 2001 |
26 other studies available for pirenzepine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Ligands; Radioligand Assay; Rats; Receptors, Muscarinic | 1992 |
Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients.
Topics: Aged; Alzheimer Disease; Dentate Gyrus; Elapid Venoms; Female; Hippocampus; Humans; Male; Parasympat | 2003 |
Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Autoradiography; Basal Ganglia; Cerebral Cortex; Female; Gyrus Cinguli; Hum | 2003 |
Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cost Savings; Dib | 2003 |
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepi | 2003 |
Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brain Chemistry; Choline O-Acetylt | 2006 |
Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Chemistry; Case-Control Studies; Dizocilpin | 2007 |
Cortical muscarinic receptor subtypes and Alzheimer's disease.
Topics: Alzheimer Disease; Benzodiazepinones; Binding, Competitive; Cerebral Cortex; Dementia; Humans; N-Met | 1982 |
Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Binding Sites; Brain; Carbachol; Frontal Lobe; GTP-Binding Proteins; Humans | 1995 |
Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbachol; Cerebral Cortex; Choline O-Acetyltransferase; | 1995 |
Diminished muscarinic receptor-stimulated [3H]-PIP2 hydrolysis in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Binding, Competitive; Carbachol; Cell Membrane; Choline O-Acetyltransferase | 1993 |
Characterization of muscarinic acetylcholine receptors in cultured adult skin fibroblasts: effects of the Swedish Alzheimer's disease APP 670/671 mutation on binding levels.
Topics: Aged; Alzheimer Disease; Amyloid beta-Protein Precursor; Cells, Cultured; Fibroblasts; Humans; Mutat | 1995 |
Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Costs | 1996 |
Synthesis and muscarinic activities of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Analysis of Variance; Animals; Bind | 1996 |
Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors.
Topics: Acetylcholine; Alzheimer Disease; Analysis of Variance; Animals; Atropine; Brain; Cholinesterase Inh | 1996 |
Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.
Topics: Acetylcholine; Aged; Alzheimer Disease; Brain; Carbachol; Cations, Divalent; Chlorides; Edetic Acid; | 1999 |
Tardive dyskinesia in older patients.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz | 2000 |
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Budgets; Clozapine; Comorbidity; Depressiv | 2001 |
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Depre | 2001 |
Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cholinergic Fibers; Dioxolanes; Dose-Response Relationshi | 2001 |
Laminar alterations in gamma-aminobutyric acidA, muscarinic, and beta adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer's disease.
Topics: Adrenergic beta-Antagonists; Aged; Alzheimer Disease; Gyrus Cinguli; Humans; Muscimol; Nerve Degener | 1991 |
Coupling of m1 muscarinic receptors to G protein in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Binding, Competitive; Cerebral Cortex; Choline O-Acetylt | 1991 |
Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbachol; Choline O-Acetyltransferase; Female; Frontal | 1991 |
Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Carbachol; Cerebral Cortex; Cholin | 1988 |
Muscarinic cholinergic receptor subtypes in normal human brain and Alzheimer's presenile dementia.
Topics: Adult; Aged; Alzheimer Disease; Binding Sites; Brain; Brain Chemistry; Humans; Pirenzepine; Receptor | 1987 |
Functional and biochemical basis for multiple muscarinic acetylcholine receptors.
Topics: Alzheimer Disease; Benzodiazepinones; Discrimination, Psychological; Humans; Kinetics; Neuroeffector | 1985 |